Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug
A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.
Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments
Meet Medela's Katie Busse, Intouch Solutions' Andrew Grojean, Heartbeat's Meghan Kate, Fingerpaint's Travis Rooke, and Havas Life Metro's Dan Sorine.
The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.
The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test
Bayer, Eli Lilly, GlaxoSmithKline, and Sanofi have suspended advertising on the show, according to news reports.
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
Several of the top-spending brands have never hired more than one female or non-white marketing boss, and some never have.
GSK pulls ads from "The O'Reilly Factor"; the FDA approves drug for Huntington's disease patients; lawmakers may remove pre-existing conditions requirement
Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Tom Noland says protecting and enhancing Humana's reputation comes down to three things: corporate volunteerism, good media relations, and content creation.
Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics
This year's festival will be held June 17 and 18.
Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law
Agency vets Nadine Leonard and James Talerico to co-lead Publicis-owned shop.
A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year
The committee is seeking information about the companies' sales and marketing strategies.
Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results
Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.
Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker
P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
AHCA set for vote; J&J halts YouTube ads; approval decisions loom for Sanofi, Roche
Healthcare is sometimes about life or death, but is almost always about quality of life, says the EVP of health system products and strategy.
The Xiidra marketing team attempted to move away from the standard drug commercial to shine in a new market and challenge legacy techniques.
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised
Researchers found that DTC advertising was associated with significant increases in testing and treatment for these drugs
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
This program is designed to enable entrepreneurs and biopharma marketers to engage in an intelligent way to explore beyond-the-pill partnerships.
Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.
Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
Marathon to sell Emflaza to PTC Therapeutics; Emma Walmsley's salary is lower than Andrew Witty's; Trump considers Medicare negotiation of drug prices
PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.
Allergan's national vision-loss-prevention campaign, See America, has brought on rapper Common as a celebrity spokesman.
The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits
Organizations are focusing on better ways to verify HCPs' digital identities.
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
SXSW's health track finally got a seat at the big-kids table.
Repatha reduces need for time-consuming procedure; Trump selects Gottlieb to lead the FDA; Acorda launches Alexa skill for MS
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.
The MM&M Transforming Healthcare Conference will be held May 1 in New York City.
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
The organization is now called Havas Health & You and continues to be led by Donna Murphy.
Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled
He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.
The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies
The new spot for its cholesterol-lowering injection debuted last week.
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
Pfizer and Bristol-Myers Squibb were the top spenders last year.
Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Valeant added 250 primary care sales reps to promote its Salix portfolio.
The joint venture pairs a communication powerhouse with a provider of defense-department-grade predictive analytics.
J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking
The health insurer partnered with Microsoft to use VR and AR technology to gather biometric data.
Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA
The network was previously called Publicis Healthcare Communications Group.
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
The report identifies four major issues of the 28% that were found to abuse IAB's standards.
Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead
Dennis Urbaniak has also been named chief digital officer at Havas Lynx.
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
The campaign would require a two-fold approach: Facebook link ads and Facebook Audience Network.
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March
The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents
Novo Nordisk appoints new CEO, and more people moves for you to know about
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
More older Americans are taking at least three psychiatric drugs; Marathon to pause launch of Emflaza; Aetna and Humana call off deal
The drugmaker worked with creative agency BBDO and PR firm Marina Maher Communications to develop the campaign.
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
The company acquired Everyday Health in December.
The new venture aims to provide clients with global reach.
Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS
Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Thursday, April 20, 2017
- Five things for pharma marketers to know: Friday, April 21, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- How pharma marketers are using behavioral science
- Veeva and QuintilesIMS tussle over customer reference data
- Genentech urges broader adoption of value-based payment models
- Some brands thought to shift online ad dollars, creating uncertainty for WebMD
- Study: Medical-marijuana laws lower prescription drug usage